Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines.
NSP Review
Engaging with South Africa’s National Strategic Plan for HIV, STIs and TB Edition 7 July – August 2013
A publication of the Treatment Action Campaign and SECTION27
GeneXpert: An imperfect rollout
TB in South African prisons: Where to now?
Decentralising DR-TB care: How far alon...g are we?
more
SOP- Quality Assurance of Malaria Diagnostic Tests
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
n Autumn 2013, HHI Executive Director, Vincenzo Bollettino, traveled to the Philippines to participate in an assessment of civil-military engagement in the humanitarian response to Typhoon Haiyan. The report was sponsored by the Center for Excellence in Disaster Management and Humanitarian Assistanc...e.
more
For close to 15 years, the Monitor has tracked the impact of victim assistance on the lives of victims of landmines, cluster munitions,
and other explosive remnants of war (hereafter “mine/ERW victims”). Over this time, the international communi...ty has strengthened its resolve to promote the rights and address the needs of victims through programs and services that are accessible and adequate in quantity, quality, availability, and consistent with the high standards set by human rights as well as other international humanitarian law.
more
Bull World Health Organ 2018;96:450–461 | doi: http://dx.doi.org/10.2471/BLT.17.206466
The aim of our study was to determine whether an intervention designed
to involve the male partners of pregnant women in Burkina Faso in facility-based maternity care influences care-seeking and healthy practi...ces after childbirth.
more
The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la...test practical guidance on use of newly recommended diagnostics as well as guidance in key technical areas, including quality assurance and quality management systems, specimen collection and registration, procurement and supply-chain management, diagnostic connectivity, biosafety, data management, human resources, strategic planning, and model algorithms. The key changes are:
inclusion of recent or updated WHO recommendations for tests to diagnose TB and detect drug resistance;
alignment with the latest WHO critical concentrations for phenotypic drug-susceptibility testing (DST) and the new definitions of pre-XDR-TB and XDR-TB;
updated information on building quality-assured TB testing and management capacity using the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) approach (Score-TB package1);
updated information on assessing, analysing and optimising TB diagnostic networks; and
updated information on the use of next-generation sequencing (NGS) to detect mutations associated with drug resistance for surveillance purposes.
The document also provides references to resources and tools relevant for work on laboratory strengthening.
more